BridgeBio Pharma, Inc. — Director's Dealing 2020

Mar 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-03-02

Reporting Person: STEPHENSON BRIAN C (See Remark)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-02	Common Stock	S	4960	$31.7946	Disposed	343356	Direct
2020-03-02	Common Stock	S	5550	$32.645	Disposed	337806	Direct
2020-03-02	Common Stock	S	290	$33.3103	Disposed	337516	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019.

F2: Represents the weighted average sale price of the shares sold from $31.26 to $32.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4.

F3: Represents the weighted average sale price of the shares sold from $32.27 to $33.25 per share.

F4: Represents the weighted average sale price of the shares sold from $33.27 to $33.36 per share.